Your browser doesn't support javascript.
loading
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.
Mohammadi, Kusha A; Brackin, Taylor; Schwartz, Gregory G; Steg, Philippe Gabriel; Szarek, Michael; Manvelian, Garen; Pordy, Robert; Fazio, Sergio; Geba, Gregory P.
Afiliação
  • Mohammadi KA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
  • Brackin T; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
  • Schwartz GG; University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Steg PG; Université Paris-Cité, Paris, France.
  • Szarek M; FACT (French Alliance for Cardiovascular Trials) INSERM U1148, Paris, France.
  • Manvelian G; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
  • Pordy R; State University of New York, Downstate School of Public Health, Brooklyn, New York, USA.
  • Fazio S; CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Geba GP; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Cancer Med ; 12(16): 16859-16868, 2023 08.
Article em En | MEDLINE | ID: mdl-37458138
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de PCSK9 / Anticorpos Monoclonais / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de PCSK9 / Anticorpos Monoclonais / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article